Skip to main content

Astrazeneca Plc(AZN-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low192.31
Day High194.83
Open:194.22
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Astrazeneca Plc

Select a category then submit the form to load news
AstraZeneca Completes Key Japan Safety Study for Imfinzi/Imjudo in Liver Cancer
AstraZeneca Wraps Real-World Lung Cancer Study, Sharpening Market Insight for AZN Investors
Guggenheim Sticks to Its Buy Rating for AstraZeneca (AZN)
AstraZeneca Sets Digitally Enabled 2026 AGM with Key Governance and Capital Votes
AstraZeneca Halts Early KRASG12D Cancer Trial, Shifting Focus in Competitive Oncology Race
AstraZeneca CEO Receives 101,495 Shares as Long-Term Incentive Award Vests
AstraZeneca Grants Long-Term Share Awards to CEO and CFO
AstraZeneca Executives Receive Vested Deferred Share Awards
Jefferies Remains a Buy on AstraZeneca (AZN)
AstraZeneca’s ATHLOS COPD Trial Nears Readout, Supporting Long-Term Respiratory Upside
Deutsche Bank Keeps Their Sell Rating on AstraZeneca (AZN)
Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)
AstraZeneca Updates Early Combo Cancer Trial, Keeping Pressure on Immuno-Oncology Rivals
AstraZeneca Completes Key Drug Interaction Study for Capivasertib, Easing Safety Overhang
AstraZeneca Confirms Updated Voting Rights Total for Shareholders
UBS Remains a Buy on AstraZeneca (AZN)
AstraZeneca Raises $2bn in Three-Tranche Global Bond Offering
AstraZeneca Files 2025 Form 20-F Annual Report with U.S. SEC
AstraZeneca Files 2025 Annual Report Ahead of April 2026 AGM
AstraZeneca refreshes board as Nazneen Rahman to retire and sustainability leadership shifts
AstraZeneca Withdraws Planned Saruparib Ovarian Cancer Trial: What Investors Should Know
AstraZeneca wins U.S. nod for first fixed-duration all-oral CLL combo
AstraZeneca’s AZD5462 Heart Failure Trial Reaches Key Mid-Stage Milestone
AstraZeneca Wraps Brazilian Real-World Breast Cancer Study, Sharpening Its Market Play in Latin America

Profile

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.